An internal standard for the quantification of oclacitinib
Related Products
Unlabeled Version(s)
18722Oclacitinib
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Oclacitinib-13C-d3

Item No. 28808

Technical Information
Formal Name
trans-N-methyl-4-(methyl-13C-d3-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-cyclohexanemethanesulfonamide
CAS Number
2750534-84-8
Molecular Formula
C14[13C]H20D3N5O2S
Formula Weight
Purity
≥99% deuterated forms (d1-d3)
A solid
DMSO: solubleMethanol: soluble
SMILES
CNS(C[C@@H]1CC[C@@H](N(C2=NC=NC3=C2C=CN3)[13C]([2H])([2H])[2H])CC1)(=O)=O
InChi Code
InChI=1S/C15H23N5O2S/c1-16-23(21,22)9-11-3-5-12(6-4-11)20(2)15-13-7-8-17-14(13)18-10-19-15/h7-8,10-12,16H,3-6,9H2,1-2H3,(H,17,18,19)/t11-,12-/i2+1D3
InChi Key
HJWLJNBZVZDLAQ-JWRHSUTGSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Kinase Resource Center
    Discover Products & Resources for Kinase Research
    • Kinase inhibitors, screening libraries, assay kits, & more
    • Tools to study kinase signaling pathways:
      • Growth factor signaling
      • PI3K/Akt/mTOR
      • MAPKs (ERK, p38, & JNK)
      • JAK/STAT signaling
    • Articles, resources, & advice
    EXPLORE NOW
    Product Description

    Oclacitinib-13C-d3 is intended for use as an internal standard for the quantification of oclacitinib (Item No. 18722) by GC- or LC-MS. Oclacitinib is an inhibitor of the JAK family kinases JAK1, JAK2, JAK3, and TYK2 (IC50s = 10, 18, 99, and 84 nM, respectively).1 It is selective for JAK kinases over a panel of 38 additional kinases at 1 μM. Oclacitinib inhibits LPS-induced increases in IL-12 and TNF-α levels in murine bone marrow-derived dendritic cells (BMDCs) in a concentration-dependent manner.2 Topical administration of oclacitinib (0.1, 0.25, and 0.5%) reduces scratching behavior and ear edema, as well as decreases levels of IL-1β, IL-4, and IL-6 in ear skin, in a mouse model of allergic dermatitis induced by toluene-2,3-diisocyanate (TDI). Formulations containing oclacitinib have been used in the treatment of pruritus associated with allergic dermatitis and the control of atopic dermatitis in dogs.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Gonzales, A.J., Bowman, J.W., Fici, G.J., et alOclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J. Vet. Pharmacol. Ther. 37(4), 317-324 (2014).

    2. Fukuyama, T., Ehling, S., Cook, E., et alTopically administered Janus-kinase inhibitors ofacitinib and olacitinib dsplay impressive antipruritic and anti-inflammatory responses in a model of allergic dermatitis. J. Pharmacol. Exp. Ther. 354(3), 394-405 (2015).